

Global efforts in combating leprosy, successes and challenges.

Whitney Anastacio*

The Wistar Institute, 3601 Spruce Street, Philadelphia, Pennsylvania 19104, USA.

Introduction

Leprosy, also known as Hansen's disease, is a chronic infectious disease caused by the bacteria *Mycobacterium leprae*. Historically one of the most feared and stigmatized diseases, leprosy has shaped societal attitudes and public health policies for centuries. This article delves into the history, symptoms, diagnosis, treatment, and ongoing challenges in eradicating this ancient affliction [1,2].

Historical perspective

Leprosy has been documented for over 4,000 years, with references found in ancient texts from India, China, and Egypt. The disease was once surrounded by myths and misconceptions, often associated with sin and moral failing. In medieval Europe, those afflicted were ostracized, confined to leprosaria (leper colonies), and subjected to various forms of social exclusion [3,4].

The bacterium responsible for leprosy, *Mycobacterium leprae*, was identified in 1873 by Norwegian scientist Gerhard Henrik Armauer Hansen, marking a significant breakthrough in understanding the disease. Despite this, the stigma persisted well into the 20th century, perpetuating the isolation and suffering of those affected [5].

Symptoms and classification

Leprosy primarily affects the skin, peripheral nerves, upper respiratory tract, and eyes. The disease manifests in a spectrum of clinical forms, broadly classified by the World Health Organization (WHO) into two main types based on the immune response of the patient: paucibacillary (PB) and multibacillary (MB).

Paucibacillary Leprosy (PB): Characterized by five or fewer skin lesions with no detectable bacteria in skin smears. The immune response is relatively strong, limiting the spread of the bacteria [6,7].

Multibacillary Leprosy (MB): Involves more than five skin lesions and a higher bacterial load, often with nerve damage. The immune response is weaker, allowing the bacteria to multiply and spread more easily.

Common symptoms include

- Skin lesions that are lighter than normal skin color and may be numb
- Thickened nerves, often in the elbows and knees

- Muscle weakness and numbness in the extremities
- Ulcers on the soles of the feet
- Eye problems that can lead to blindness if untreated

Diagnosis and Treatment

Diagnosing leprosy involves a combination of clinical signs, patient history, and laboratory tests. Skin smears and biopsies can confirm the presence of *Mycobacterium leprae*. In regions with limited access to laboratory facilities, diagnosis is often based on visible symptoms and physical examination [8,9].

The introduction of multidrug therapy (MDT) in the 1980s revolutionized leprosy treatment. MDT, recommended by the WHO, typically includes a combination of rifampicin, dapson, and clofazimine. The duration of treatment varies: six months for PB and 12 months for MB leprosy. MDT is highly effective, killing the bacteria and curbing transmission, and it is provided free of charge by the WHO globally.

Global efforts and challenges

Significant progress has been made in reducing the global leprosy burden. The WHO's goal of eliminating leprosy as a public health problem—defined as reducing the prevalence to less than one case per 10,000 population—was achieved in most countries by the early 2000s. However, leprosy has not been eradicated, and pockets of the disease persist, particularly in India, Brazil, and Indonesia, which account for about 80% of new cases annually.

Ongoing challenges in leprosy control include:

- **Stigma and Discrimination:** Social stigma remains a significant barrier to early diagnosis and treatment. Many patients delay seeking help due to fear of ostracization.
- **Access to Healthcare:** In remote and impoverished regions, access to healthcare services is limited, hindering early diagnosis and consistent treatment.
- **Post-Treatment Complications:** Patients may suffer from nerve damage and disability even after successful treatment, requiring long-term rehabilitation and support.

Future Directions

Eradicating leprosy requires sustained efforts in public health education, early diagnosis, and continuous treatment. Innovative approaches are being explored, including:

*Correspondence to: Whitney Anastacio, The Wistar Institute, 3601 Spruce Street, Philadelphia, Pennsylvania 19104, USA. E-mail: anastacio@whitney.org

Received: 18-May-2024, Manuscript No. aarcd-24-140860; Editor assigned: 21-May-2024, PreQC No. aarcd-24-140860(PQ); Reviewed: 25-May-2024, QC No. aarcd-24-140860; Revised: 17-June-2024, Manuscript No. aarcd-24-14086 (R); Published: 08-July-2024, DOI:10.35841/aarcd-7.3.206.

- **Enhanced Diagnostic Tools:** Development of rapid diagnostic tests to detect leprosy in its early stages.
 - **Vaccination:** Research into vaccines that could provide immunity against *Mycobacterium leprae* is ongoing. The Bacillus Calmette-Guerin (BCG) vaccine, primarily used against tuberculosis, has shown some protective effects against leprosy.
 - **Genomic Research:** Advances in genomics may provide insights into the genetic factors that influence susceptibility to leprosy, potentially leading to targeted therapies [10].
2. Cross H. The prevention of disability for people affected by leprosy: Whose attitude needs to change?. *Leprosy review*. 2007;78(4):321-329.
 3. Kim D, Shin JI, Yoo IY, et al. GenoMycAnalyzer: A web-based tool for species and drug resistance prediction for *Mycobacterium* genomes. *BMC genomics*. 2024;25(1):387.
 4. Gallagher A. Trafficking in persons report. *Human Rights Quarterly*. 2001;23(4):1135-41.
 5. Hampton T. Collaborative effort targets 17 tropical diseases for control, elimination. *JAMA*. 2012;307(8):772.

Conclusion

Leprosy is a disease deeply rooted in human history, marked by significant medical and social challenges. While modern medicine has made great strides in controlling and treating leprosy, the journey towards complete eradication is ongoing. Continued global efforts, enhanced public awareness, and scientific advancements hold promise for a future where leprosy is no longer a public health threat. Reducing stigma, improving healthcare access, and supporting affected individuals are crucial steps in this endeavor, ensuring that the legacy of leprosy becomes one of triumph over adversity.

References

1. Krismawati H, Rochman MF, Oktavian A, et al. Sustained Actions in Combating Neglected Tropical Diseases during the COVID-19 Pandemic: Lessons Learned From the Leprosy Program in the Hyper-Endemic Area in Papua Province, Indonesia. *Frontiers in Tropical Diseases*. 2022;2:782255.
6. Ploemacher T, Faber WR, Menke H, et al. Reservoirs and transmission routes of leprosy; A systematic review. *PLoS neglected tropical diseases*. 2020;14(4):e0008276.
7. Teixeira CS, Pescarini JM, Alves FJ, et al. Incidence of and factors associated with leprosy among household contacts of patients with leprosy in Brazil. *JAMA dermatology*. 2020;156(6):640-648.
8. Jafferany M. Psychodermatology: When the mind and skin interact: understanding the link between cutaneous and psychiatric disorders to improve outcomes. *Psychiatric Times*. 2011;28(12):26-.
9. James WD, Elston D, Berger T. Andrew's diseases of the skin E-book: Clinical dermatology. *J Res Health Sci*. 2011.
10. McInturff JE, Modlin RL, Kim J. The role of toll-like receptors in the pathogenesis and treatment of dermatological disease. *J Invest Dermatol*. 2005;125(1):1-8.

Citation: Anastacio W. *Global efforts in combating leprosy, successes and challenges*. *Res Clin Dermatol*. 2024;7(3):206.